[
    "{\"step_by_step_thinking\": \"Semagacestat is a \u03b3-secretase inhibitor developed as a potential treatment for Alzheimer's disease. However, according to the documents, clinical trials of Semagacestat were terminated before completion due to a recommendation by the data and safety monitoring board. The ADAS-cog scores, which indicate cognitive impairment, worsened in all groups including those receiving Semagacestat. The ADCS-ADL scores, which indicate better functioning, also worsened in all groups including those receiving Semagacestat. Furthermore, patients treated with Semagacestat experienced more adverse events, including skin cancers and infections. Therefore, it can be concluded that Semagacestat is not effective for Alzheimer's Disease.\", \"answer_choice\": \"B\"}"
]